当前位置: X-MOL 学术Aliment. Pharm. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: A multicenter study in Japan
Alimentary Pharmacology & Therapeutics ( IF 7.6 ) Pub Date : 2024-04-23 , DOI: 10.1111/apt.17995
Tsubasa Tsutsumi 1 , Takumi Kawaguchi 1 , Hideki Fujii 2 , Yoshihiro Kamada 3 , Hirokazu Takahashi 4 , Miwa Kawanaka 5 , Yoshio Sumida 6 , Michihiro Iwaki 7 , Hideki Hayashi 8 , Hidenori Toyoda 9 , Satoshi Oeda 4, 10 , Hideyuki Hyogo 11 , Asahiro Morishita 12 , Kensuke Munekage 13 , Kazuhito Kawata 14 , Koji Sawada 15 , Tatsuji Maeshiro 16 , Hiroshi Tobita 17 , Yuichi Yoshida 18 , Masafumi Naito 18 , Asuka Araki 17 , Shingo Arakaki 16 , Hidenao Noritake 14 , Masafumi Ono 19 , Tsutomu Masaki 12 , Satoshi Yasuda 9 , Eiichi Tomita 8 , Masato Yoneda 7 , Akihiro Tokushige 20 , Shinichiro Ueda 20 , Shinichi Aishima 21 , Atsushi Nakajima 7 , Takeshi Okanoue 22
Affiliation  

A multi-stakeholder consensus has proposed MASLD (metabolic dysfunction-associated steatotic liver disease). We aimed to investigate the pathological findings related to the mid-term mortality of patients with biopsy-proven MASLD in Japan.

中文翻译:


肝脏炎症和纤维化与活检证实的 MASLD 的中期死亡率相关:日本的一项多中心研究



多利益相关者共识提出了 MASLD(代谢功能障碍相关的脂肪肝病)。我们的目的是调查日本经活检证实的 MASLD 患者与中期死亡率相关的病理学结果。
更新日期:2024-04-23
down
wechat
bug